These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700 [TBL] [Abstract][Full Text] [Related]
24. [The update of emerging targeted therapies of lung cancer]. Shang CC; Zhang L Zhonghua Nei Ke Za Zhi; 2017 Jun; 56(6):447-449. PubMed ID: 28592047 [No Abstract] [Full Text] [Related]
25. Molecular targeted agents and biologic therapies for non-small cell lung cancer. Somaiah N; Simon GR J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S434-54. PubMed ID: 21102235 [No Abstract] [Full Text] [Related]
26. Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer. Pirker R Clin Adv Hematol Oncol; 2008 Oct; 6(10):735-6. PubMed ID: 18997663 [No Abstract] [Full Text] [Related]
27. New targets for non-small-cell lung cancer therapy. Alvarez M; Roman E; Santos ES; Raez LE Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567 [TBL] [Abstract][Full Text] [Related]
29. [Immune Checkpoint Therapy for Non-Small-Cell Lung Cancer]. Miyauchi E; Inoue A Gan To Kagaku Ryoho; 2016 Jun; 43(6):666-71. PubMed ID: 27306803 [TBL] [Abstract][Full Text] [Related]
30. The new drugs and biologics as sensitizers in the treatment of non-small cell lung cancer. Turrisi AT Suppl Tumori; 2002; 1(4):S55-7. PubMed ID: 12415822 [No Abstract] [Full Text] [Related]
32. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? Joerger M; Finn SP; Cuffe S; Byrne AT; Gray SG Expert Opin Ther Targets; 2016 Nov; 20(11):1339-1356. PubMed ID: 27353429 [TBL] [Abstract][Full Text] [Related]
33. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Comis RL Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313 [No Abstract] [Full Text] [Related]
34. Discovery of drug resistance biomarker could improve cancer treatment. Pharmacogenomics; 2013 Jan; 14(2):125. PubMed ID: 23447824 [No Abstract] [Full Text] [Related]
35. The HLJ1-targeting drug screening identified Chinese herb andrographolide that can suppress tumour growth and invasion in non-small-cell lung cancer. Lai YH; Yu SL; Chen HY; Wang CC; Chen HW; Chen JJ Carcinogenesis; 2013 May; 34(5):1069-80. PubMed ID: 23306212 [TBL] [Abstract][Full Text] [Related]
37. Non-small cell lung cancer: from targeted therapy to tailored therapy. Malgieri S; Feliciano S; Bosso D; Federico P; Palmieri G; De Placido S; Di Lorenzo G; Buonerba C Expert Opin Pharmacother; 2012 Sep; 13(13):1817-9. PubMed ID: 22803703 [No Abstract] [Full Text] [Related]
38. The tissue is the issue: personalized medicine for non-small cell lung cancer. Hirsch FR; Wynes MW; Gandara DR; Bunn PA Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402 [TBL] [Abstract][Full Text] [Related]
39. MAPK pathway: a potential target for the treatment of non-small-cell lung carcinoma. Pradhan R; Singhvi G; Dubey SK; Gupta G; Dua K Future Med Chem; 2019 Apr; 11(8):793-795. PubMed ID: 30994024 [No Abstract] [Full Text] [Related]
40. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Ettinger DS Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]